Overview

AUY922 in Patient With Stage IV NSCLC

Status:
Completed

Trial end date:
2017-02-01

Target enrollment:

Participant gender:

Summary

This is an open-label, single-arm, multicenter phase II trial in patients with stage IV EGFR T790M, EGFR exon 20 and other uncommon, HER2, or BRAF-mutated; ALK, ROS1, or RET-rearranged NSCLC.

Phase:

Phase 2

Details

Lead Sponsor:

National Taiwan University Hospital